沙美特罗替卡松对不同血清载脂蛋白A水平慢性阻塞性肺疾病患者的疗效分析

Analysis of the Efficacy of Salmeterol and Fluticasone on Different Serum Apolipoprotein A Levels in Patients With Chronic Obstructive Pulmonary Disease

目的分析沙美特罗替卡松对不同血清载脂蛋白A水平慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)患者的治疗效果。方法选择2021年1月—2023年1月六盘水市人民医院收治的176例COPD患者为研究对象。以载脂蛋白A 0.6 g/L为临界点,按照患者载脂蛋白A水平将其分为高载脂蛋白组(n=100)、低载脂蛋白组(n=76)。所有患者均使用沙美特罗替卡松气雾剂治疗,50~500μg/次,1次/d,治疗6个月。比较2组患者干预前后肺功能指标情况、不良反应发生率、临床症状指标。结果干预前,2组患者的第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))以及预计值百分比的第1秒用力呼气容积(FEV_(1)%pred)比较,差异有统计学意义(P<0.05)。干预后,2组患者的FEV_(1)以及FEV_(1)%pred较干预前均有所提升,差异有统计学意义(P<0.05),干预后组间比较,差异无统计学意义(P>0.05)。低载脂蛋白组不良反应发生率为14.47%,高载脂蛋白组不良反应发生率为14.00%,2组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。低载脂蛋白组住院时间、急性发作次数、发作间隔时间分别为(15.98±0.18)d、(1.25±0.26)次、(172.25±20.25)d;高载脂蛋白组分别为(15.97±0.17)d、(1.24±0.25)次、(171.98±20.26)d。2组患者的住院时间、急性发作次数、发作间隔时间比较,差异无统计学意义(P>0.05)。结论对不同血清载脂蛋白A水平COPD患者,应用沙美特罗替卡松治疗效果相当,其药效不受身体代谢状态影响,值得临床推广。

Objective To analyze the therapeutic effects of salmeterol/fluticasone on patients with chronic obstructive pulmonary disease(COPD)with different serum apolipoprotein A levels,aiming to provide reference material for related research work.Methods A total of 176 COPD patients admitted to the People's Hospital of Liupanshui City from January 2021 to January 2023,were selected as the research subjects.Based on the difference in apolipoprotein A levels of the patients,they were divided into the high apolipoprotein group(n=100)and the low apolipoprotein group(n=76),with 0.6 g/L as the critical point.Patients were treated with salmeterol/fluticasone inhalation aerosol,with a dosage of 50 to 500μg per time,once daily,for a period of 6 months.The lung function indicators,incidence of adverse reactions,and clinical symptom indicators between two groups of patients before and after intervention were compared.Results Before treatment,there was a statistically significant difference in the forced expiratory volume in one second(FEV_(1))and the forced expiratory volume in the first second in percent predicted values(FEV_(1)%pred)between the two groups of patients(P<0.05).After treatment,the FEV_(1) and FEV_(1)%pred of the two groups of patients improved compared to before intervention(P<0.05),and there was no statistically significant difference in the relevant data between groups after treatment(P>0.05).The incidence of adverse reactions in the low apolipoprotein group was 14.47%,and the incidence of adverse reactions in the high apolipoprotein group was 14.00%.There were no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).The hospitalization time,number of acute attacks,and interval between attacks in the low apolipoprotein group were were(15.98±0.18)days,(1.25±0.26)times,and(172.25±20.25)days,respectively;the high apolipoprotein group were(15.97±0.17)days,(1.24±0.25)times,and(171.98±20.26)days,respectively.There were no statistically significant difference in hospitalization time,number of acute attacks,and interval between attacks between the two groups of patients(P>0.05).Conclusion For COPD patients with different serum apolipoprotein A levels,the use of salmeterol and fluticasone to treat the disease can both achieve satisfactory results.The efficacy is not affected by the body's metabolic status,which is worth further promotion and application in clinical practice.